Convatec Group PLC (CTEC), the global medical technology company, has disclosed the purchase of 1,858,645 ordinary shares during the week of 9 to 13 November 2026, executed through Morgan Stanley & Co. International plc. The transactions form part of the Company's share buyback programme of up to $200 million, which was announced on 4 August 2026. All purchased shares will be held in treasury, reducing the number of shares available to outside investors. The disclosure provides shareholders with an updated denominator figure for calculating notifiable interests under FCA transparency rules.
Key Points
- Convatec Group PLC (CTEC) is a global medical technology company listed on the London Stock Exchange
- The Company purchased 1,858,645 ordinary shares of 10 pence each across five trading sessions between 9 and 13 November 2026
- Purchases were made at prices ranging from 247.40p (lowest) to 258.60p (highest) per share; all shares are being held in treasury
- Investors should watch the pace of the remaining buyback capacity relative to the $200m programme ceiling announced in August 2026
Daily Breakdown of Convatec's Share Purchases Across Five Trading Sessions
The announcement details purchases across each of the five trading days. On 9 November 2026, the Company acquired 50,348 shares at a volume weighted average price (VWAP) of 250.68p. The largest single-day purchase occurred on 10 November, when 650,447 shares were bought at a VWAP of 249.55p. On 11 November, 385,443 shares were acquired at a VWAP of 252.66p, followed by 207,798 shares on 12 November at 255.55p. The week concluded on 13 November with 564,609 shares purchased at a VWAP of 257.48p, the highest average of the five sessions.
Convatec's Treasury Share Position and Total Voting Rights Following These Transactions
Following completion of these purchases, Convatec now holds 140,535,613 ordinary shares in treasury. The total number of ordinary shares in issue, excluding treasury shares, stands at 1,909,253,946. Under FCA Disclosure Guidance and Transparency Rules, this figure of 1,909,253,946 represents the total voting rights in the Company and serves as the denominator shareholders must use when assessing whether they are required to notify a change in their interest in Convatec. The buyback transactions were executed by Morgan Stanley & Co. International plc on the Company's behalf.
Convatec's $200m Buyback Programme Context and Investor Considerations
The share buyback programme, originally announced on 4 August 2026, has a total authorised size of up to $200 million. Convatec operates in the medical technology sector, providing products focused on chronic care, including wound care and ostomy management, across global markets. Buyback programmes of this nature are typically used to return capital to shareholders and can support earnings per share over time. Investors may wish to monitor subsequent weekly disclosures to track the cumulative value deployed against the $200m programme ceiling, though the Company did not disclose remaining programme capacity in this announcement.





Please wait processing your request...